Key result
Research output on SGLT2 inhibitors in cardiovascular diseases increased significantly from 2014 to 2024, with 1,271 articles analyzed highlighting heart failure and renal protection as dominant themes.
Why the study?
Research on SGLT2 inhibitors in cardiovascular science has expanded rapidly over the past decade, motivating a bibliometric evaluation of global research trends, publication output, citation impact, and collaboration networks from 2014 to 2024.
Bibliometric analysis reveals a rapid and significant expansion of research on SGLT2 inhibitors in cardiovascular science over the past decade, driven by major clinical trials and global collaborations.
Answers are grounded in this paper and cite their sources.
Reflects surging SGLT2 inhibitor research post-2020; leaves open optimal clinical translation and guideline integration.
Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have gained significant attention in cardiovascular science due to their cardioprotective and Reno protective effects beyond glucose control. Over the past decade, research in this field has expanded rapidly. This study aims to conduct a bibliometric analysis of global research trends on SGLT2 inhibitors in cardiovascular diseases from 2014 to 2024, evaluating publication output, citation impact, influential contributors, keyword trends, and international collaboration networks. Methods: A bibliometric analysis was performed using the Web of Science (WoS) Core Collection database, focusing on articles published between January 1, 2014, and December 31, 2024, within the “cardiac cardiovascular system” category. VOSviewer software was utilized to visualize author collaborations, institutional affiliations, keyword co-occurrence, and citation distributions. Results: A total of 1,271 articles were analyzed. Research output has increased significantly, particularly after 2020, aligning with key clinical trials on SGLT2 inhibitors. The most prolific journals included Cardiovascular Diabetology, Journal of the American College of Cardiology, and European Journal of Heart Failure. Leading institutions such as Harvard Medical School, University of Toronto, and University of Groningen were identified as major contributors. Citation analysis highlighted high-impact studies on SGLT2 inhibitors’ cardiovascular and renal benefits. Keyword co-occurrence analysis showed that heart failure, diabetes mellitus, and renal protection were dominant themes. The United States, Germany, and China emerged as major players in global collaborations, shaping the research landscape. Conclusion: The bibliometric findings suggest that research on SGLT2 inhibitors in cardiovascular diseases is rapidly evolving, with increasing global contributions and high-impact publications shaping clinical applications. Future studies should focus on long-term cardiovascular and renal outcomes, mechanistic insights, and comparative effectiveness research to further establish SGLT2 inhibitors’ role in cardiovascular medicine.
No takes yet. Share an insight, caveat, or question.
Ahmet Yılmaz (2025) conducted a review in Cardiovascular diseases (n=1,271). SGLT2 inhibitors was evaluated on Publication output, citation impact, influential contributors, keyword trends, and international collaboration networks. Research output on SGLT2 inhibitors in cardiovascular diseases increased significantly from 2014 to 2024, with 1,271 articles analyzed highlighting heart failure and renal protection as dominant themes.
Synapse has enriched 10 related papers. Consider them for comparative context: